CLVT
Clarivate Plc
Clarivate Plc (CLVT) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 52.5, with 0/3 trend checks passing.
CLVT with MA50 and MA200
Key levels & signals
Clarivate Plc (CLVT) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $2.34, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 1.8% and below the 200-day moving average by 17.9%.
CLVT currently has an RSI reading of 52.5, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing CLVT next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Clarivate Plc
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.
Learn the indicators behind this page
More stock opportunities
Common questions about CLVT
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.
